期刊
JOURNAL OF BLOOD MEDICINE
卷 4, 期 -, 页码 141-147出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/JBM.S45071
关键词
cerebral amyloid angiopathy; A beta 40; chronic inflammatory; cerebral vessel
类别
资金
- National Natural Science Foundation of China [81170481, 81200352]
- Shanghai Pujiang Program [11PJ1403200]
- Innovation Fund of Shanghai Municipal Education commission [12zz040]
- SRF for ROCS
Cerebral amyloid angiopathy (CAA) is a critical factor in the pathogenesis of Alzheimer's disease (AD). In the clinical setting, nearly 98% AD patients have CAA, and 75% of these patients are rated as severe CAA. It is characterized by the deposition of the beta-amyloid peptide (mainly A beta 40) in the walls of cerebral vessels, which induces the degeneration of vessel wall components, reduces cerebral blood flow, and aggravates cognitive decline. Platelets are anuclear cell fragments from bone marrow megakaryocytes and their function in hemostasis and thrombosis has long been recognized. Recently, increasing evidence suggests that platelet activation can also mediate the onset and development of CAA. First, platelet activation and adhesion to a vessel wall is the initial step of vascular injury. Activated platelets contribute to more than 90% circulating A beta (mainly A beta 1-40), which in turn activates platelets and results in the vicious cycle of A beta overproduction in damaged vessel. Second, the uncontrolled activation of platelets leads to a chronic inflammatory reaction by secretion of chemokines (eg, platelet factor 4 [PF4], regulated upon activation normal T-cell expressed and presumably secreted [RANTES], and macrophage inflammatory protein [MIP-1 beta]), interleukins (IL-1 beta, IL-7, and IL-8), prostaglandins, and CD40 ligand (CD40L). The interaction of these biological response modulators with platelets, endothelial cells, and leukocytes establishes a localized inflammatory response that contributes to CAA formation. Finally, activated platelets are the upholder of fibrin clots, which are structurally abnormal and resistant to degradation in the presence of A beta 42. Thus, opinion has emerged that targeting blood platelets may provide a new avenue for anti-AD therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据